• Roflumilast cream atopic dermatitis trial completes enrollment

    1 month ago - By Healio

    Arcutis Biotherapeutics has completed patient enrollment for its phase 3 trial of roflumilast cream for the treatment of atopic dermatitis, the company announced in a press release.
    The parallel group, double blind, vehicle controlled INTEGUMENT-1 trial includes 654 adults and children aged 6 years and older with at least 3% body surface area involvement of AD.
    Participants will receive roflumilast cream 0.15%, a PDE4 inhibitor, or vehicle to apply once daily for four weeks.
    “Atopic dermatitis is a chronic condition that typically begins in childhood. The red, itchy rash most frequently
    Read more ...